What Revolution Biomanufacturing does

Revolution Biomanufacturing Inc. (DBA: RBIx) is a privately held, 100% American-owned biomanufacturing company — certified as Disabled Veteran-Owned and Woman-Owned — that provides cGMP manufacturing and process development services for mRNA therapeutics and personalized medicine. The company operates from a GMP facility at 17 Briden Street, Worcester, Massachusetts, and is led by CEO Molly S. McGlaughlin. Its stated mission is to shorten the path from tumor sequencing to patient dosing for individualized therapies, serving biotech developers of personalized mRNA therapeutics and pharmaceutical companies requiring compliant mRNA manufacturing capacity.

The company's offerings are organized into three interconnected service pillars: (1) Process Science and Innovation, covering innovative UTR and codon design, DNA template engineering, mRNA IVT process development, downstream purification, lipid nanoparticle encapsulation, formulation development, and microbial cell line and fermentation work; (2) cGMP Manufacturing, providing end-to-end production from mRNA synthesis through LNP formulation to fill-finish and final product release under global regulatory standards; and (3) Regulatory Strategy and Project Management, supporting IND, NDA, and BLA submissions, regulatory gap assessments, and outsourcing project management. The technology stack is conventional bioprocessing rather than AI-native, and the firm has also expanded into microbial fermentation and purification of proteins.

The business model is professional services-based with quote-based, non-public pricing tailored to each client and therapeutic application. Go-to-market is direct enterprise field sales targeting biotech and pharmaceutical customers, with lead intake via the company website, contact form, email ([email protected]), and LinkedIn. The company markets itself as an integrated alternative to fragmented CDMO offerings by combining process development, manufacturing, and regulatory expertise under one roof, and it is positioning to capture federally funded research through its FCOI compliance posture and ownership certifications.

Name

Revolution Biomanufacturing

Legal name

Revolution Biomanufacturing Inc.

Website

https://revolutionbiomanufacturing.com

Company type

Private

Founded year

2025

Operating status

Operating

Headcount range

1–10 employees

Short description

Revolution Biomanufacturing Inc. is a Worcester, MA-based CDMO providing end-to-end cGMP mRNA manufacturing, process development, and regulatory strategy services for biotech and pharmaceutical companies developing personalized therapeutics, including cancer vaccines and individualized mRNA treatments.

Ownership category

akta.pro rank

Product category

Biopharmaceutical Contract Manufacturing

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

mRNA/LNP & Nucleic Acid Therapeutics CDMO (HLAGABAF)

akta.pro secondary industries

Process Development & Tech Transfer Services (upstream/downstream) (HLAAAKAF), Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK), GMP Quality, Validation & Regulatory Support (GMP/CSV/Qualification) (HLAGAGAL)

Keywords

• MRNA biomanufacturing services
• CGMP contract manufacturing
• Process development services
• Lipid nanoparticle formulation
• Regulatory strategy consulting

Headquarters

HQ city

Canton

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Infrastructure, Technology or R&D, Operations, Supply Chain

Revenue model

1. cGMP Manufacturing Services: End-to-end cGMP manufacturing from mRNA synthesis and LNP formulation to fill-finish and final product release for clinical and commercial personalized medicine products
2. Process Development Services: Process science and innovation services including UTR and codon design, DNA template engineering, mRNA IVT optimization, and downstream purification process development
3. Regulatory Strategy and Project Management: Expert regulatory strategy development, IND/NDA/BLA submission support, regulatory gap assessments, and outsourcing project management services
4. LNP Formulation Services: Lipid nanoparticle encapsulation and formulation development services for enhanced mRNA delivery

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Revolution Biomanufacturing is a contract development and manufacturing organization (CDMO) providing end-to-end mRNA biomanufacturing services for personalized therapeutics. Its offerings span process science and innovation (UTR/codon design, DNA template engineering, IVT optimization, downstream purification, LNP encapsulation, formulation development), cGMP manufacturing of mRNA drug substances and fill-finished products, and regulatory strategy and project management for IND, NDA, and BLA submissions. Services are delivered from a USA-based GMP facility in Worcester, Massachusetts.

Product overview

Revolution Biomanufacturing Inc. is a pioneering mRNA biomanufacturer offering an integrated suite of services for personalized medicine development. The company's portfolio consists of three interconnected service pillars: Process Science and Innovation (covering mRNA synthesis optimization, DNA template engineering, LNP formulation, and formulation development), cGMP Manufacturing (end-to-end production from mRNA synthesis to fill-finish), and Regulatory Strategy and Project Management (IND/BLA submission support and regulatory compliance). Together, these services are designed to streamline the path from tumor sequencing to patient dosing, enabling biotech partners to bring life-saving mRNA-based therapies to market with speed and reliability.

Differentiator

Problem solved

Functional benefit

Products and services

• Process Science and Innovation Comprehensive process development solutions for mRNA manufacturing, including innovative UTR and codon design, DNA template engineering, cell line development for microbial and mammalian expressed proteins, mRNA IVT process development, downstream purification, lipid nanoparticle encapsulation, formulation development, and alternative material solutions. Intended for biotech and pharmaceutical companies developing personalized mRNA therapeutics.
• cGMP Manufacturing Scalable cGMP manufacturing solutions for mRNA drug substances and fill-finished products, operating in full compliance with global regulatory standards for personalized medicine production. Capabilities include end-to-end production from mRNA synthesis and LNP formulation to fill-finish and final product release, plus microbial fermentation and purification of proteins. Intended for biotech and pharmaceutical clients requiring compliant, right-sized clinical and commercial manufacturing.
• Regulatory Strategy and Project Management Expert regulatory strategy development and outsourcing project management services, including guidance on IND, NDA, and BLA submissions, regulatory gap assessments, and compliance optimization for streamlined commercialization. Designed for biotech and pharmaceutical partners navigating complex global regulatory pathways for innovative mRNA-based therapies.

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature8 records

Scale indicators2 records

Recent moves5 records

Expansion highlights4 records

Emerging players

• eTheRNA immunotherapies: mRNA-focused biotechnology company offering mRNA design, LNP formulation, and manufacturing services for partners. Comparable as a smaller specialized mRNA player with overlapping service offerings.
• GenScript ProBio: CDMO division of GenScript offering plasmid, mRNA, viral vector, and cell therapy manufacturing services. Comparable as an emerging mRNA/nucleic acid CDMO targeting similar biotech customers.
• Kernal Biologics: US-based mRNA therapeutics developer with proprietary LNP and selective mRNA technology. Comparable as a small emerging mRNA-focused player operating in adjacent parts of the mRNA value chain.

Direct peers

• Aldevron: Major CDMO for plasmid DNA, mRNA, and protein biologics used in cell and gene therapies. Comparable as a nucleic acid-focused CDMO serving therapeutic developers requiring GMP-grade material.
• CureVac: mRNA technology company with proprietary manufacturing capabilities and offering mRNA production services. Comparable as an mRNA-focused organization with GMP manufacturing infrastructure.
• TriLink BioTechnologies: A leading CDMO specializing in mRNA, oligonucleotides, and nucleic acid manufacturing with GMP capabilities. Most directly comparable peer given shared focus on mRNA/LNP production for therapeutic developers.
• BioNTech IMFS (Idenix Manufacturing & Services): External mRNA and lipid nanoparticle CDMO arm of BioNTech offering end-to-end GMP manufacturing. Highly comparable given shared focus on integrated mRNA/LNP CDMO services.

Broad incumbents

• Lonza: One of the world's largest CDMOs with established mRNA, lipid nanoparticle, and biologics manufacturing capabilities across multiple modalities. Represents the broad incumbent against which smaller mRNA CDMOs compete.
• Catalent: Large diversified CDMO with nucleic acid, biologics, and fill-finish capabilities used by mRNA developers including during COVID-19 vaccine scale-up. Comparable as a broad incumbent offering overlapping services.
• WuXi Biologics: Global biologics CDMO with growing nucleic acid and mRNA manufacturing capacity. Comparable as a large incumbent CDMO offering GMP mRNA and LNP services to therapeutic developers.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/revolutionbiomanufacturing

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Revolution Biomanufacturing